Clinical trial · Observational
GDPE/CEOPE Compared With CEOPE for Newly Diagnosed Patients With PTCL
GDPE/CEOPE Compared With CEOPE as the First-line Therapy for Newly Diagnosed Patients With Peripheral T-Cell Lymphoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Peripheral T-cell Lymphoma (PTCL) is a heterogenic malignancy with poor outcome. There is no standardized treatment protocol for this kind of lymphoma. So, clinical trials are encouraged by National Comprehensive Cancer Network (NCCN) for those patients. Former studies confirmed that GDP (Gemcitabine, Dexamethasone, and Cis-platinum) is superior with CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisone). Combination with etoposide can improve the outcome of some patients with high risk factors. The aim of our study is to compare the response and survival rate of GDPE/CEOPE (gemcitabine, cis-platinum, etoposide, and dexamethasone/cyclophosphamide, vincristine, pharmorubicin, etoposide, and prednisone) with those of CEOPE regimen, looking forward to its superiority in efficacy and safety for the newly diagnosed adult patients with PTCL.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gemcitabine | — | UNRESOLVED | — |
| PTCL | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- test group
- description
- patients with PTCL who receive GDPE/CEOPE as the first-line therapy strategy
- label
- control group
- description
- patients with PTCL who receive CEOPE as the first-line therapy strategy
Primary outcomes (1)
- measure
- RR
- timeFrame
- 1 year
- description
- Response Rate (including complete response \& partial response)
Secondary outcomes (1)
- measure
- PFS
- timeFrame
- 1 year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Peripheral T Cell Lymphoma, Not Otherwise Specified * Angioimmunoblastic T Cell Lymphoma * ALK-negative Anaplastic Large Cell Lymphoma * Enteropathy Associated T Cell Lymphoma * Subcutaneous Panniculitis Like T Cell Lymphoma * Acute T-cell Leukemia/Lymphoma Exclusion Criteria: * woman in pregnancy or lactation * allergic to any intervention drug * unsuitable to the study due to severe complication * enrolled to other study during the past 6 months * NK/T lymphoma ALK-positive Anaplastic Large Cell Lymphoma
References
Publications (0)
Data not yet available